tetano
Editor, Senior Moderator
Liver Transpl
. 2021 Dec 17.
doi: 10.1002/lt.26389. Online ahead of print.
Decreased Long-term SARS-CoV-2-Specific Humoral Immunity in Liver Transplant Recipients 12-Months after COVID-19
Aránzazu Caballero-Marcos[SUP] 1 2 [/SUP], María Jesús Citores[SUP] 3 [/SUP], Roberto Alonso-Fernández[SUP] 4 [/SUP], Manuel Rodríguez-Perálvarez[SUP] 2 5 [/SUP], Maricela Valerio[SUP] 4 [/SUP], Javier Graus Morales[SUP] 6 [/SUP], Valentín Cuervas-Mons[SUP] 7 8 [/SUP], Alba Cachero[SUP] 9 [/SUP], Carmelo Loinaz-Segurola[SUP] 10 [/SUP], Mercedes Iñarrairaegui[SUP] 11 [/SUP], Lluís Castells[SUP] 2 12 [/SUP], Sonia Pascual[SUP] 13 [/SUP], Carmen Vinaixa-Aunés[SUP] 2 14 [/SUP], Rocío González-Grande[SUP] 15 [/SUP], Alejandra Otero[SUP] 16 [/SUP], Santiago Tomé[SUP] 17 [/SUP], Javier Tejedor-Tejada[SUP] 18 [/SUP], Ainhoa Fernández-Yunquera[SUP] 1 2 [/SUP], Luisa González-Diéguez[SUP] 19 [/SUP], Flor Nogueras-Lopez[SUP] 20 [/SUP], Gerardo Blanco-Fernández[SUP] 21 [/SUP], Fernando Díaz-Fontenla[SUP] 1 2 [/SUP], Francisco Javier Bustamante[SUP] 22 [/SUP], Mario Romero-Cristóbal[SUP] 1 2 [/SUP], Rosa Martin-Mateos[SUP] 6 [/SUP], Ana Arias-Milla[SUP] 7 [/SUP], Laura Calatayud[SUP] 23 [/SUP], Alberto A Marcacuzco-Quinto[SUP] 10 [/SUP], Víctor Fernández-Alonso[SUP] 1 [/SUP], Concepción Gómez-Gavara[SUP] 12 [/SUP], Patricia Muñoz[SUP] 4 [/SUP], Rafael Bañares[SUP] 1 2 [/SUP], José Antonio Pons[SUP] 24 [/SUP], Magdalena Salcedo[SUP] 1 2 [/SUP]
Affiliations
Abstract
Long-term humoral immunity and its protective role in liver transplant patients has not been elucidated. We performed a prospective multicenter study to assess the persistence of IgG antibodies in liver transplant recipients 12 months after coronavirus disease 2019 (COVID-19). A total of 65 liver transplant recipients were matched with 65 non-transplanted patients by a propensity score including variables with recognized impact on COVID-19. Liver transplant recipients showed a lower prevalence of anti-nucleocapsid (27.7% vs. 49.2%, P = 0.02) and anti-spike IgG antibodies (88.2% vs. 100.0%, P = 0.02) at 12 months. Lower index values of anti-nucleocapsid IgG antibodies were also observed in transplant patients one year after COVID-19 (0.49 [IQR 0.15-1.40] vs. 1.36 [IQR 0.53-2.91], P < 0.001). Vaccinated liver transplant recipients showed higher antibody levels compared to unvaccinated patients (P < 0.001); antibody levels reached after vaccination were comparable to those observed in non-transplanted individuals (P = 0.70). In liver transplant patients, a longer interval since transplantation (OR=1.10, 95% CI 1.01-1.20) was independently associated with persistence of anti-nucleocapsid IgG antibodies one-year postinfection. In conclusion, compared with non-transplanted patients, liver transplant recipients show a lower long-term persistence of anti-SARS-CoV-2 antibodies. However, SARS-CoV-2 vaccination after COVID-19 in liver transplant patients achieves a significant increase in antibody levels, comparable to that of non-transplanted patients.
Keywords: immunosuppression; long-term antibody response; vaccine immunogenicity.
. 2021 Dec 17.
doi: 10.1002/lt.26389. Online ahead of print.
Decreased Long-term SARS-CoV-2-Specific Humoral Immunity in Liver Transplant Recipients 12-Months after COVID-19
Aránzazu Caballero-Marcos[SUP] 1 2 [/SUP], María Jesús Citores[SUP] 3 [/SUP], Roberto Alonso-Fernández[SUP] 4 [/SUP], Manuel Rodríguez-Perálvarez[SUP] 2 5 [/SUP], Maricela Valerio[SUP] 4 [/SUP], Javier Graus Morales[SUP] 6 [/SUP], Valentín Cuervas-Mons[SUP] 7 8 [/SUP], Alba Cachero[SUP] 9 [/SUP], Carmelo Loinaz-Segurola[SUP] 10 [/SUP], Mercedes Iñarrairaegui[SUP] 11 [/SUP], Lluís Castells[SUP] 2 12 [/SUP], Sonia Pascual[SUP] 13 [/SUP], Carmen Vinaixa-Aunés[SUP] 2 14 [/SUP], Rocío González-Grande[SUP] 15 [/SUP], Alejandra Otero[SUP] 16 [/SUP], Santiago Tomé[SUP] 17 [/SUP], Javier Tejedor-Tejada[SUP] 18 [/SUP], Ainhoa Fernández-Yunquera[SUP] 1 2 [/SUP], Luisa González-Diéguez[SUP] 19 [/SUP], Flor Nogueras-Lopez[SUP] 20 [/SUP], Gerardo Blanco-Fernández[SUP] 21 [/SUP], Fernando Díaz-Fontenla[SUP] 1 2 [/SUP], Francisco Javier Bustamante[SUP] 22 [/SUP], Mario Romero-Cristóbal[SUP] 1 2 [/SUP], Rosa Martin-Mateos[SUP] 6 [/SUP], Ana Arias-Milla[SUP] 7 [/SUP], Laura Calatayud[SUP] 23 [/SUP], Alberto A Marcacuzco-Quinto[SUP] 10 [/SUP], Víctor Fernández-Alonso[SUP] 1 [/SUP], Concepción Gómez-Gavara[SUP] 12 [/SUP], Patricia Muñoz[SUP] 4 [/SUP], Rafael Bañares[SUP] 1 2 [/SUP], José Antonio Pons[SUP] 24 [/SUP], Magdalena Salcedo[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34919762
- DOI: 10.1002/lt.26389
Abstract
Long-term humoral immunity and its protective role in liver transplant patients has not been elucidated. We performed a prospective multicenter study to assess the persistence of IgG antibodies in liver transplant recipients 12 months after coronavirus disease 2019 (COVID-19). A total of 65 liver transplant recipients were matched with 65 non-transplanted patients by a propensity score including variables with recognized impact on COVID-19. Liver transplant recipients showed a lower prevalence of anti-nucleocapsid (27.7% vs. 49.2%, P = 0.02) and anti-spike IgG antibodies (88.2% vs. 100.0%, P = 0.02) at 12 months. Lower index values of anti-nucleocapsid IgG antibodies were also observed in transplant patients one year after COVID-19 (0.49 [IQR 0.15-1.40] vs. 1.36 [IQR 0.53-2.91], P < 0.001). Vaccinated liver transplant recipients showed higher antibody levels compared to unvaccinated patients (P < 0.001); antibody levels reached after vaccination were comparable to those observed in non-transplanted individuals (P = 0.70). In liver transplant patients, a longer interval since transplantation (OR=1.10, 95% CI 1.01-1.20) was independently associated with persistence of anti-nucleocapsid IgG antibodies one-year postinfection. In conclusion, compared with non-transplanted patients, liver transplant recipients show a lower long-term persistence of anti-SARS-CoV-2 antibodies. However, SARS-CoV-2 vaccination after COVID-19 in liver transplant patients achieves a significant increase in antibody levels, comparable to that of non-transplanted patients.
Keywords: immunosuppression; long-term antibody response; vaccine immunogenicity.